How Companies in Brazil Can Source Pharma Products & CDMO Services (2026 Guide)
Brazil • Source Pharma Products & CDMO Services
Introduction
Brazil is the largest pharmaceutical market in Latin America, and its regulator is one of the most demanding in the region. Brazilian companies import a wide mix of inputs: active pharmaceutical ingredients (APIs) for local formulation, finished generics, sterile injectables, biologics, and contract manufacturing (CDMO) services for brands that want to add products without building new capacity.
This guide covers where supply comes from, how to qualify a foreign manufacturer for ANVISA (Agência Nacional de Vigilância Sanitária), which import documents you need, and the problems that most often delay a first shipment. For background, see our overview of the Brazilian pharmaceutical market and the Brazil country hub.
Where supply comes from
Most Brazilian buyers build a supply base that matches each product's complexity, price and regulatory history.
| Supply base | What buyers typically source | What to check |
|---|---|---|
| India and China | Generic APIs, intermediates, high-volume oral solids and many finished generics | ANVISA GMP certification of the site, Zone IVb stability data, impurity profiles |
| Europe (EU-GMP) | Complex generics, sterile injectables, hormones, specialty and niche products | EU-GMP certificate in the EudraGMDP database, capacity for Portuguese packs |
| United States | Specialty, biologic and high-value products, some APIs | FDA inspection history, export certificates such as the COPP |
| Argentina, Mexico and other regional sources | Finished products for Latin American portfolios, biosimilars, contract packaging | Mercosur origin rules, artwork changes from Spanish to Portuguese |
| South Korea and Japan | Biosimilars, specialty injectables, selected APIs | Cold chain planning for long transits |
Brazil also has a large domestic industry, so many imports are inputs for local production. For critical molecules, qualify two sources in different regions so one inspection finding or port delay does not stop supply.
Pharma categories supply
Demand comes from the public health system (SUS), pharmacy chains, private hospitals and a large generics segment.
- APIs and intermediates: analgesics, antidiabetics, cardiovascular and anti-infective molecules for local formulators. The API source is part of the registration file, so changing it is a regulatory change.
- Finished generics: tablets, capsules and oral liquids for chronic disease. Brazil distinguishes reference, generic and similar medicines, and generics need bioequivalence against the Brazilian reference product.
- Sterile injectables and oncology: vials, ampoules and prefilled syringes for hospitals and public tenders.
- Biologics and biosimilars: often supplied through technology-transfer arrangements with public laboratories, known as productive development partnerships.
- OTC products and supplements: food supplements follow a separate ANVISA framework from medicines.
- CDMO services: contract manufacturing, packaging and stability studies.
How to source pharma products
- Define the product and the route. Fix the molecule, strength, dosage form and pack size. Decide whether you need a new registration, a transfer of an existing one, or supply for a tender or exceptional import.
- Confirm the local holder. ANVISA registrations are held by a Brazilian company with an operating authorisation (AFE) that covers importation. A foreign manufacturer cannot hold the registration itself, so the importer or a regulatory partner takes that role.
- Shortlist qualified sites. Ask for current GMP certificates (WHO-GMP, EU-GMP, US FDA or a PIC/S authority) and check whether the site already holds ANVISA GMP certification (CBPF). Whether ANVISA must inspect the site has a big effect on your timeline.
- Review the technical file. Request a CTD-structured dossier, CoAs for recent batches, long-term stability data at 30°C/75% RH, bioequivalence studies against the Brazilian reference product where relevant, and full API documentation.
- Agree commercial terms. Settle MOQ, lead time, Incoterms, Portuguese artwork and who pays for any ANVISA inspection.
- Test before scaling. Order samples or a pilot batch and have it tested by a Brazilian laboratory before committing to volume.
PharmaTradz works with GMP-certified manufacturers and CDMOs across Asia, Europe, the Americas and Africa, including sites with Latin American registration experience. You can send one structured requirement through our request for quotation page instead of chasing suppliers one by one. If you need help building or adapting the file, see our dossier licensing and registration support.
Required documents for import
Imports are checked by ANVISA and by the Federal Revenue Service (Receita Federal) through the Siscomex single window. Prepare these documents before goods leave origin.
Regulatory documents
- ANVISA registration number, or the authorisation for an exceptional import
- The importer's AFE and, for controlled substances, the special authorisation (AE)
- Certificate of Pharmaceutical Product (COPP) in WHO format, where requested
- GMP certificate of the manufacturing site and its ANVISA CBPF
- Certificate of Analysis for each batch, matching the registered specifications
- Import licence with ANVISA consent in Siscomex, which for many products must be registered before shipment
Commercial and shipping documents
- Commercial invoice and packing list showing batch numbers and expiry dates
- Bill of lading or air waybill
- Certificate of origin, if you claim Mercosur or other tariff preferences
- Temperature records for cold-chain consignments
- Safety data sheet for APIs and hazardous materials
Documents presented to ANVISA often need a Portuguese translation.
Logistics and shipping
Main entry points
- Sea: the Port of Santos in São Paulo state handles most pharmaceutical containers. Paranaguá, Itajaí and Rio de Janeiro serve the south and southeast.
- Air: São Paulo/Guarulhos (GRU) and Viracopos in Campinas (VCP) are the main air cargo gateways for medicines. Rio de Janeiro/Galeão (GIG) is an alternative.
Indicative transit times
| Origin | Sea freight to Santos | Air freight to São Paulo |
|---|---|---|
| South and East Asia | Typically 30 to 45 days | Typically 3 to 7 days |
| Europe | Typically 15 to 25 days | Typically 1 to 3 days |
| Mercosur neighbours | Road freight or short-sea, typically under 10 days | Typically 1 to 2 days |
Add time for customs and ANVISA release; a physical inspection can add several days.
Cold chain, Incoterms and customs
Vaccines, biologics and many injectables need 2 to 8°C control from the factory to the warehouse. Use GDP-qualified forwarders, validated packaging and data loggers, and confirm cold storage at the arrival airport before booking. Many buyers use FCA or CIP for air and FOB or CIF for sea; whoever controls the freight should carry the temperature risk. A customs broker who knows ANVISA-controlled goods is worth the fee on early shipments.
Legal and regulatory overview
- Regulator: ANVISA, linked to the Ministry of Health. Brazil is a member of ICH and PIC/S.
- Registration holder: a Brazilian company with an AFE. Foreign manufacturers work through a local holder.
- GMP: manufacturing sites need ANVISA GMP certification. ANVISA inspects or, in some cases, relies on equivalent authorities.
- Dossier: ANVISA's submission structure broadly follows CTD content, and electronic CTD (eCTD) is being introduced in phases.
- Stability: Zone IVb, with long-term conditions of 30°C/75% RH.
- Pricing: CMED, the drug market regulation chamber, approves a maximum price before a medicine can be sold.
- Labelling: labels and the package insert (bula) must be in Portuguese and follow ANVISA rules.
- Timelines: registration of a new generic typically takes a year or more, depending on the product category, the review queue and any priority status.
Routes without a full registration
Unregistered medicines enter Brazil only in limited cases: exceptional imports authorised by ANVISA during shortages or public health needs, supplies for authorised clinical trials, and imports for individual patients with a prescription. Public buyers purchase through tenders under the public procurement law (Law 14.133/2021), and tender supply generally needs an ANVISA-registered product.
Common challenges and practical solutions
| Challenge | Practical solution |
|---|---|
| Long ANVISA review queues | File a complete dossier the first time, use priority routes where you qualify, and plan launches around realistic timelines. |
| Foreign site not yet certified by ANVISA | Check CBPF status before signing. Favour sites already certified or inspected by PIC/S authorities. |
| Missing Zone IVb stability data | Ask for 30°C/75% RH data at the first contact and budget for new studies if it is missing. |
| Portuguese labels and bula | Agree in the contract who owns the artwork, and have the holder's regulatory team approve final proofs. |
| API supplier changes | Treat any new API source as a post-approval change and qualify alternates early. |
| Holds at the port | Align the invoice, import licence and labels line by line, and use a broker experienced with ANVISA. |
Most of these problems start with missing information. A short technical questionnaire sent to every shortlisted supplier saves months later.
Conclusion
Sourcing for Brazil works when the regulatory plan comes before the purchase order. Pick the route, confirm the local holder, check ANVISA GMP status and Zone IVb data, and then compare prices across regions. Asian sources often win on generic APIs and volume products, while European and US sites remain the usual choice for complex sterile and biologic products.
PharmaTradz helps Brazilian importers and brand owners reach qualified manufacturers in every major supply region. Before the first order, read our guide on how to verify a pharmaceutical supplier.
Frequently Asked Questions
Can a foreign manufacturer hold an ANVISA registration?
No. The registration must be held by a Brazilian company with an ANVISA operating authorisation (AFE). Foreign manufacturers work through an importer or a regulatory partner that acts as holder.
Which stability zone applies to products sold in Brazil?
Brazil is Zone IVb. Long-term stability studies are expected at 30°C/75% RH, so data generated only at 25°C/60% RH is not enough.
Does ANVISA inspect factories outside Brazil?
Yes. ANVISA certifies foreign sites for GMP through its own inspection or, in some cases, by relying on equivalent authorities. Confirm the site's status before signing.
Do medicines sold in Brazil need Portuguese labelling?
Yes. Labels and the package insert must be in Portuguese and follow ANVISA rules.
Can unregistered medicines be imported into Brazil?
Only in limited cases, such as exceptional imports authorised by ANVISA during shortages, clinical trial supplies, or imports for an individual patient with a prescription.
Who sets medicine prices in Brazil?
CMED approves the maximum price of each medicine before sale, based on a request from the registration holder.
More on Brazil
Source Pharma Products & CDMO Services — other markets
Planning to register or source in Brazil?
Tell us the molecule, dosage form and target market. We will come back on the regulatory pathway and whether the project is realistic before you commit anything.
Submit a Requirement Ask a questionIf you already hold WHO-GMP, EU-GMP, USFDA or PIC/S approval, you are closer to supplying Brazil than you probably think.
Brazil's regulator publishes a register of authorised products. Look up any supplier's claims yourself — including ours.
